Customer concentration
A few distributors account for a large share of worldwide gross sales, so pricing or volume changes can quickly affect revenue.
- Scope
- Cencora, McKesson, Cardinal Health and major retail pharmacies
- Materiality
- high
Embecta Corp.
Embecta Corp. is a U.S.-based diabetes care company spun out of BD in 2022 that sells injection devices used to deliver insulin and other diabetes therapies. Its core business is a global portfolio of pen needles, syringes, and safety injection devices sold through distributors, retail pharmacies, hospitals, and other healthcare channels in more than 100 countries.
26,2 %
62,6 %
8,8 %
−3,8 %
2.41
1.73
| % | |
|---|---|
| Pen needles | 55% Sterile, single-use needles used with pen injectors to deliver insulin and other diabetes drugs. |
| Safety pen needles | 20% Needles with protective shields designed to reduce needlestick exposure during injection and disposal. |
| Syringes | 15% Traditional diabetes syringes used for injectable therapy and related administration needs. |
| Safety injection devices and accessories | 10% Other injection-related products supporting safe and convenient diabetes drug administration. |
Embecta sells primarily into the diabetes care ecosystem, where demand is driven by patients using insulin or other...
- Wholesale distributorsprimary
Cencora, McKesson, Cardinal Health and similar distributors buy in bulk and resell into pharmacy and healthcare channels.
- Retail pharmaciesprimary
Large pharmacy chains and independent pharmacies buy Embecta products for direct sale to diabetes patients.
- Hospitals and institutional buyerssecondary
Hospitals and other institutions buy injection devices for clinical use and patient discharge needs.
- End users with diabetesprimary
Patients ultimately use the products for insulin and other injectable diabetes therapies, driving repeat demand.
- Healthcare professionalssecondary
Physicians and diabetes care professionals influence product adoption, training, and therapy administration choices.
Embecta operates a global manufacturing and distribution network and sells into more than 100 countries...
- •Sales and distribution in over 100 countries
- •Manufacturing sites in Ireland, the United States, and China
- •Global commercial reach through retail, hospitals, and pharmacies
- •International operations expose the company to tariffs and trade barriers
- •Brand and license transfers across countries remain operationally important
Embecta’s strategy is centered on protecting its core diabetes injection franchise while improving operational...
01
Brand transition and license transfershort-term
Embecta must rebrand products and transfer registrations to avoid commercialization disruptions.
02
Operational independence from BDshort-term
The company needs to replace transition services and business continuity processes to run as a standalone public company.
03
Portfolio expansion through partnerships and M&Amedium-term
New technologies and complementary products could reduce dependence on legacy injection devices and open new markets.
04
Patch pump and product development initiativesmedium-term
New diabetes delivery technologies are needed to defend against competitive and therapeutic shifts.
Embecta is exposed to concentrated customer and product risk because a few distributors and a small number of core...
Dependence on core products
The company generates significant profits and cash flow from a limited set of diabetes injection products.
- Scope
- Pen needles, syringes, safety devices
- Materiality
- high
Separation and rebranding execution
Failure to transfer licenses, registrations, and product branding could interrupt commercialization and distribution.
- Scope
- BD transition, regulatory registrations, supply chain systems
- Materiality
- high
Leverage and refinancing risk
Large debt obligations consume cash flow and may limit future borrowing or dividend capacity.
- Scope
- Term loan and notes outstanding
- Materiality
- high
Competitive and technology disruption
New drug therapies, pumps, and injection technologies can reduce demand for legacy devices.
- Scope
- Diabetes care market
- Materiality
- high
Separation and restructuring charges
Operating income and cash flow
Revenue timing through distributors
Revenue and gross margin
Lease accounting
Operating expenses and liabilities
Debt and interest accounting
Net income, cash flow, and leverage metrics
Impairment and intangible assets
Earnings and asset values
: 28.4.2026